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may be less likely to report themselves in poor or excellent health than people in other countries even with the same 'true' quality of life. To some extent, we control for this by comparing health for people with and without particular conditions. As a further test, we repeat our analysis using a more objective measure of health: the number of impairments in basic Activities of Daily Living (ADLs) that the person has. Our results are virtually identical in considering ADL impairments as in looking at self-reported health, however, so we reject this explanation.
The second hypothesis we consider is that the US does better for richer, well insured people than for poorer, uninsured people, and these differences are reflected in the prevalence of particular conditions. However, we show that our results are the same when we divide each country into rich and poor, as when we consider them together. Thus, this explanation is not supported.
We finally propose, and provide limited evidence for, an alternative explanation: the US does much better in conditions where high-tech medicine is the key to better health, and worse in conditions where low -tech management of chronic disease is more important. This hypothesis matches the ranking of the diseases. Heart disease and strokes are the two conditions where hightech medicine is most valuable, and they are the two where the US does best. Diabetes is a condition where chronic disease management is vital, and the US does worst. With the data at hand, we are unable to prove whether high-tech care and poor chronic disease management are the source of the differing results, but we suggest empirical tests that could be helpful.
The rest of the paper is organized as follows. Section 1 describes the methodology.
Section 2 describes the data and the institutional environment of the four countries we consider.
Section 3 presents our main results, and section 4 discusses possible interpretations. The last section concludes.
I. Methods
When comparing the effect of medical care on non-fatal health across countries, we have several options. One option is to look at the prevalence of particular diseases across countries.
This is an important outcome, but it suffers from two problems. First, and most importantly, prevalence of disease will be influenced by many factors in addition to medical care. Thus, one would need to be cautious about such an interpretation. Second, prevalence alone does not account for the severity of the impairment -how much does the health system alleviate the adverse impact of diseases.
To focus particularly on what medical care can do to influence health, we consider the health of people who have particular conditions, ignoring the possible role of medical care in disease prevention. Even here, there are methodological choices about how to compare health.
One strategy is to undertake physical observations of people with different diseases and have experts (or non-experts) rate those observations. This is a good strategy, and we pursue it to some extent below. But physical assessment of life with diseases is limited, and omits the enormous contribution that mental and other non-physical attributes (such as pain) play in health.
Further, even experts in the field may not know what it is like to live with particular diseases.
We thus take an alternate approach to measuring the impact of the medical system.
Following Cutler and Richardson (1997 , we compare the self-reported health of people who have a condition to self-reported health of people who do not have that condition.
These self-reports are the individual's own assessment of their current health state. Self-assessed health of the people with a condition are on average below those of people without the condition (as one would expect). The degree to which self-reports of those with a condition fall below those without a condition is an indictor of the quality of life for people with that condition. We can compare these quality of life differentials across countries.
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We formalize this idea with a little notation. We assume that people have a latent measure of health h*, which depends on the diseases they have D, demographic characteristics X such as sex, income or education, and the country C. Countries treat diseases differently, and hence each disease may affect the health outcomes of people who live there differently . We express health of people i in country j as:
where ß, and ? are vectors of parameters to be estimated. The interaction of disease indicators with country dummies allows for the differential effect of having each condition in each country.
We interact d emographic variables with country dummies to allow for variation along this dimension as well.
In practice, we do not observe h*, the underlying health measure. We do observe discrete approximations to it, denoted h. In our primary specification, the questions that we consider are about self -reported overall health status (SRHS), generally framed as: "How would you rate your health: excellent, very good, good, fair or poor?" Previous research shows that SRHS is a good predictor of mortality as well as of other health outcomes, with people who rate their health as poor being more likely to die or to have a bad health outcome (Long and Marshall, 1999; Mossey and Shapiro, 1982; Kaplan et al., 1988; Idler et al., 1990) .
With a distributional assumption on ε , we can relate the underlying variable to its discrete approximation. In particular, if we assume that ε is normally distributed, we can estimate equation 1 using an ordered probit model. This model, in addition to the coefficients of the previous specification, will also give us estimates of c 1 , c 2 and c 3 , the break points between the four different health states (the four states are defined below).
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The ß and ? coefficients in our model range from +∞ to -∞. To normalize the results, we divide our coefficients by the difference between the cut points of very good/excellent health and poor/very poor health, e.g., β β as the difference between perfect health and death, this would correspond to the quality-adjusted life expectancy associated with each health state. We thus term these QALY measures. Even if one is not willing to make this assumption, however, the scaling provides a useful benchmark.
Self-reported health status is not necessarily a perfect measure of health. The very nature of the self-report raises some questions. For instance, it could be the case that diseases has the same effect on the health of the population in different countries, but that people perceive the impacts differently for cultural reasons. As noted above, we believe our within-country comparison controls for this. We can test this further, however, using physical measures of impairment in addition to self-reported. We thus estimate models using impairments in activities of daily living (ADLs, including the ability to perform certain daily habits such as bathing, dressing, walking or eating) as the dependent variable. As we show below, the results are similar with the two measures.
II. Selection of Countries and Data
We focus our analysis on the health of the elderly. In developed countries, the elderly are virtually the only group with significant health impairments, so it makes sense to focus on that group. We analyze the health of the elderly in four countries: the US, Canada, the UK, and
Spain. The countries were chosen partly because they have available data, and partly because their health systems are so different. The main characteristics of the four systems are summarized below and spending trends are shown in Figure 1 . 4 
The United States
The United States spends the most on medical care of the four countries in our sampleindeed, the most of any country. Spending was $3538 per person (PPP applied), or 13.2 percent of GDP, in 1994 5 (roughly the time of our data). The US health care system is a mix of public and private insurance. There is near universal coverage for the elderly under Medicare, but some health impairments of the elderly will have resulted from conditions occurring earlier in life, when private insurance is more common. The receipt and quality of private insurance is related to income. About 15 percent of the US population is without health insurance, most predominantly the near poor population.
Health insurance in the United States is frequently quite generous on the demand-side.
Patients pay relatively little for using care, and traditionally faced few restrictions on which providers they can access. This is still true among the elderly, although there is a ma jor exception: Medicare does not cover costs of outpatient prescription medications. In the nonelderly population, cost sharing is also low ; most people with insurance can access medical care without a major financial barrier.
On the supply-side, the system is mixed. Much of private health insurance is 'managed', with explicit utilization restrictions placed on providers and financial incentives inducing them to use less care. But there are no overall constraints on technological availability, the way there are in other countries. 4 A comparison of the problems faced by medical care systems internationally is in Cutler (2002) . 5 All spending data are from the OECD Health Data (2002).
The National Health Interview Survey (NHIS) is the most common source of information on disease prevalence and health status for the US, and it has been conducted annually since
1957. Each year it includes a core set of questions on health-related variables, with periodic supplements that include more detailed information for certain populations or diseases. In 1994, the NHIS conducted the Second Supplement on Aging (the first was in 1984), containing detailed information about health conditions and physical functioning. We use the SOA data in our analysis. The sample is about 110,000 people.
Canada
Canada is the second most expensive system among our four countries, spending over 9 percent of GDP on medical care in the mid-1990s. Canada has a national insurance system (Medicare), which covers people from cradle to grave. 6 The Canadian system is administered separately in the provinces and territories, but for our purposes the similarities are more important than the differences.
Coverage in Canada is relatively complete; there are few restrictions on the providers that people can see. As in the US, however, pharmaceutical coverage is spotty. Some provinces cover prescription medications for particular groups such as the elderly, and others do not. 
The United Kingdom
The United Kingdom is a negative outlier in almost all medical spending comparisons.
Spending on medical care is only about 7 percent of GDP. Given the fact that spending as a share of GDP typically rises with income, and that the UK is relatively wealthy, this makes spending be particularly low.
The National Health Service (NHS) in the UK dates from 1948. All legal residents are eligible for health care coverage. in addition to the public coverage, people are allowed to purchase supplemental private insurance, or to pay physicians privately for services. About 10.5 percent of the UK population ha d private insurance in 1995 7 .
Accessing health care in the UK generally costs a patient very little. Most health care is free of charge at the point of use, although there is some cost sharing for some services, including pharmaceuticals. This cost sharing is waived for the elderly (and children). As with Canada, spending in the UK is limited on the supply-side. The government restricts funding for hospitals 7 Source: Laing and Buisson (1997) and monitors technology acquisition. Both of these steps limit the availability of high-tech resources.
Service efficiency has been a chronic problem in the UK. The perception of the UK system is one of long lines and non-monetary restrictions on service use. Patients must have a referral from a general practitioner to access specialist care. Urgent cases may be seen soon, but non-urgent cases can have a substantial delay. To address these issues, the government in 1990
attempted to create an 'internal market' in medical services, where patients can choose their primary care 'fundholder', and primary care providers can shop among hospitals for the best care.
The internal market was partially successful in improving the efficiency of the system (Propper and Soderlund, 1998) , but not wholly. hospitals and ambulatory clinics. In the Spanish health system, specialists from general hospitals rotate to cover for outpatient ambulatory services
As with Canada and the UK, Spain also uses supply-side restrictions to control spending, although there are some differences across autonomous communities. Most communities use an annual budget for hospital payments but a few (i.e. Catalonia) use a mixed funding system where the annual budget is combined with a DRG (Diagnostic Related Group) system.
On many measures, the Spanish medical care system works very well. Accessibility is among the highest in Europe, with 92 percent of the patients having to wait one day or less for a consultation with a GP (Ortún and López-Casasnovas, 1999) . Moreover, despite the fact that GPs serve as gatekeepers, patients do not need a referral to see some specialists. All health care areas have at least one main hospital and they are organized in such a way that nearly everyone lives within an hour of a general hospital. Because of the centralized nature of provision, Spain can make large-scale changes in medical care quickly. As we discuss below, Spain has emphasized strongly some measures of preventive care, such as treatment of diabetes.
To measure health in Spain, we use data from the Encue sta Nacional de Salud de España (ENSE). The ENSE collects information about health status as well as access to care, visits to specialists, and pharmaceutical consumption. The survey contains extra information for the elderly (ADLs) and for children 16 or younger (diet, vaccination, breast-feeding). The survey includes about 9,000 people and it started in 1993, continuing every two years thereafter. In our study we include data for 1993, 1995 and 1997.
Questions about Self -Reported Health
All four surveys ask about self-reported health, with relatively similar questions.
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However, the possible responses vary slightly by countries. In the US and Canada, there are five 12 For instance, the US NHIS asks "would you say that your health in general is excellent, very good, good, fair or poor?". The Canadian National Population Health Survey asks: "in general, how would you describe responses: "poor", "fair", "good", "very good" and "excellent". In the UK and Spain, the five responses are slightly different: "very poor", "poor", "fair", "good" and "very good". Our withincountry differencing methodology should adjust for these differences in possible responses, but it is important to understand what effect such a wording choice can have.
To examine this, we take advantage of the fact that the US added the "very good" choice in 1981. Prior to that year, there were only four possible responses. Table 1 fair, good, and very good or excellent. We order the responses from 1 to four in that order.
Selection of Conditions
The NHIS in the US contains information on a vast array of chronic conditions, as well as other measures of health such as ADL impairments. Unfortunately, this is not the case for all countries, where the prevalence questions are much more limited. This is particularly true in the UK, where the survey is not a dedicated health questionnaire. In light of this, and in order to be able to compare the US with as many countries as possible, we use several sets of comparison questions. In the first set of results, we compare only the US and Canada, since these are the countries for which the most conditions in common are asked about (14 total). The second set of results extends the analysis to include Spain, with fewer health conditions in common (9 conditions). The last set of results is for all four countries. These results have the least common conditions (8 conditions).
your health: excellent; very good; good; fair; poor". The British Household Panel Survey asks "please think back over the last 12months about how your health has been. Compared to people of your own age, would you say that your health has on the whole been: excellent, good, fair, poor, very poor?". The Spanish ENSE asks "in the last 12 months, would you say that your health has been very good, good, fair, bad, or very bad?" In addition to choosing comparable conditions, we need to account for the fact that different countries might have different awareness of certain diseases, with some countries diagnosing certain conditions more frequently. If this is the case, we might find that a country does very well in the treatment of a certain disease simply because there is more awareness and more mild cases are being diagnosed.
To examine this, Table 2 presents the prevalence of these health conditions in the four countries. We present prevalence estimates for the overall population and for the elderly. In most of the cases there are no major differences in prevalence across countries. The exceptions to this are skin or allergy conditions and visual impairments. The US has almost double the share of people suffering from skin or allergy conditions, while it has a much lower percentage of its population suffering from visual impairments.
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Given this, when analyzing our results we downweight the results for these two conditions, and focus instead on the others.
III. Main Results
We present our main results in three tables. Table 3 compares the US and Canada, the countries with the most data. in Canada are relatively better off than they are in the US. The fact that the interaction term is less than the main effect in the first row indicates that even in Canada, people with diabetes are not in better health than people without diabetes.
The interaction terms between the Canada dummy and the different illnesses are not of a uniform sign. The US does statistically significantly better in the treatment of strokes, heart problems, arthritis, asthma or bronchitis, and hearing, but it does poorly in the treatment of diabetes. There are no significant differences in the treatment of hypertension, migraines, stomach problems (ulcers and other digestive problems) and back problems. Our regression also includes demographic and socioeconomic explanatory variables. As expected, income and education have a positive effect on health and age has a negative effect, with older people being less healthy. Sex has no significant effect. This pattern of findings is generally true in comparing the US and Spain as well. The US does better than Spain in heart conditions, asthma, hearing conditions , and arthritis. Spain does significantly better than US in the treatment of diabetes and hypertension. The relatively poor performance of the US in care for diabetics is a common theme of our findings.
While not the immediate focus of our results, we comment on the Spain-Canada comparisons as well. In general, there is no clear winner between the two countries. Spanish people suffering from diabetes are clearly better off than those from Canada, but Canadians with arthritis are better off than Spanish with arthritis. Most other conditions are about the same.
Income and education have a positive effect on health in all three countries, although the income effect is more important for the US and Canada than for Spain, and education is more important for the US. Again, age has a negative effect in health, although this effect decreases as people grow older.
Finally, Table 5 includes all four countries: the US, Canada, Spain and UK. Compared to the other countries, people in the US with heart and circulatory conditions, arthritis and hearing conditions still report themselves to be in the best health, while people with diabetes and stomach conditions report themselves worse off. Once again, Spain is the country with the best treatment for diabetes and the worst treatment for arthritis. Canadians with hearing problems are worse off then in any other country.
To help with summary interpretations, Table 6 shows the relative ranking of countrie s by conditions. More *'s in any cell indicate that the country does better. Looking at any particular country yields a mixed result -every country does well for some conditions and worse for others.
Overall, these results lead us to reject the hypothesis that the US has clearly superior outcomes compared to other developed countries. The US has better outcomes for heart disease, asthma or bronchitis , and arthritis, and significantly worse outcomes for diabetes and stomach problems. We cannot say that higher spending in the US buys significantly improved health across the board.
IV. Possible Explanations
The important question raised by the previous section is how to explain the differing results across countries. We raise and test three explanations.
Differences Between Rich and Poor
One possible explanation for these results is that outside of the US, countries have universal coverage systems, while that is not true in the US. As a result, the US may have better outcomes for the insured (since overall medical spending is the highest), but worse outcomes for the uninsured. In the elderly population that we analyze, of course, there is no difference in insurance status in the US; virtually everyone over age 65 in the US is enrolled in Medicare. But there are differences in insurance coverage in the non-elderly population, and these may translate into health differences during the retirement years.
To test this hypothesis, we separate our population into two groups: poor and non-poor, and we run the same model for the two types. Poor is not synonymous with uninsured, but the two are correlated. Since we do not know about lifetime insurance coverage in the NHIS, income while elderly is a reasonably proxy. To classify people as "poor" we look at the whole population 18 or older and determine the level corresponding to the lower thirty-third percentile for that country. Any individual that has an income below the thirty-third percentile level is poor. We use income data for the entire population because we want to know the level of income for the elderly in the society as a whole, not just among the older population.
The third and fifth columns of Tables 3 to 5 (table 5) . The results are similar to the previous ones. For conditions where the US does better than the other countries, it does better for both poor and non-poor, and for conditions where the US does less well than the other countries, both poor and non-poor do less well. We thus reject the hypothesis that the pattern of results is explicable by differing effects by income.
Subjective Health Reporting
There are several possible limitations in using self-reported health status as a measure of an individual's health. One important concern is that people in different countries may perceive their health differently for cultural reasons. If people in Canada are less likely to report their health as very bad, this could influence our results. Norming by the overall population responses controls for this to some extent, but may not do so completely. Responses outside the typical range of the overall population may not be well captured by this adjustment.
To test for this, we have repeated the results using a more objective health measure: the number of ADLs that the individual has. ADLs are basic measures of functional status reflecting the ability to live independently and without substantial assistance. Not all countries ask about the same ADLs. As with our earlier regressions, we look at the common ADLs for each set of countries. The number of common conditions declines as we include more countries.
In particular, comparing the US and Canada, we can measure consistently 6 ADLs:
preparing meals, shopping for groceries, walking, showering, doing light housework and doing heavy housework. When we add Spain to the sample, we drop one ADL (doing heavy housework). There were no common questions between the UK and Canada regarding their population's ability to perform certain activiti es of daily living, but the UK, Spain, and the US each asked about two different ADLs: difficulty in dressing, and walking. Hence our last analysis compares just these three countries.
There are a few, relatively minor, differences between this specification of the model and the previous one. The first one is due to the fact that we had to use the data from the NHIS Second Supplement on Aging for the US and hence we have a lower number of observations. 14 Also, given that our dependent variable is not qualitative, we use an OLS specification instead of an ordered probit. Note in interpreting the results that a higher number of ADL impairments is worse health; thus, a positive effect of an explanatory variable implies that the individual is worse off. Tables 7 through 9 show the results for the number of ADL impairments. The results of this analysis are very similar to those using self-reported health. As expected, for all the three columns, the different health conditions have a positive effect on the number of ADLs and hence, a negative effect on the individual's health. Once again, the US has a positive performance in the treatment of heart problems and a negative one for the treatment of diabetes. 15 This is true when we compare the US and Canada, or when we add Spain and the UK to the samples. Our results using the number of ADLs as a measure of health thus strongly confirm our previous findings.
Acute Versus Chronic Disease
A third explanation is suggested by our findings: the US does relatively better at conditions where acute treatment is needed and relatively worse at chronic conditions. The comparison of heart disease and diabetes is particularly revealing. Heart disease is frequently treated in an acute setting, while diabetes is generally managed as a chronic disease. This could substantially influence the impact of medical care on health.
Heart Disease. Many individuals who report having had ischemic heart disease will have suffered from an acute event -a heart attack, angina, or other related condition. In such cases, there are many acute therapies that can be performed, along with ongoing chronic care. For a person who has a heart attack, for example, diagnostic surgical interventions such as cardiac catheterization may be used, and treatment may consist of intensive surgical procedures such as open heart surgery or angioplasty. 16 The medical literature shows that these therapies can affect quality of life, in addition to length of life (Brorsson et al., 2002; Sedrakyan at al., 2003; Hlatky et al., 1997) .
Medical systems that spend a lot can afford much more of this high-tech care than systems that spend less. The US spends the most on medical are and uses these intensive 15 We have repeated this analysis separating the sample into the poor and non-poor groups. Again, the results are similar to those for self-reported health.
16 Cardiac catheterization is a diagnostic test that involves passing a fine tube (catheter) through a blood vessel to the heart and into a coronary artery. Bypass surgery involves opening the chest wall and creating a new blood path around the occluded artery. Angioplasty is a technique for treating narrowing or occlusion of a blood vessel or heart valve by introducing a balloon into the constricted area to widen it.
procedures the most. This is shown empirically in figures 2, 3, and 4, which present the utilization rate for cardiac catheterization, bypass surgery, and angioplasty. In each case, the figures are scaled to the population as a whole. 17 The US uses these procedures far more than do other countries; use is three to five times greater in the US. The other three countries use them much less, and do so at relatively similar rates.
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This matches up with self-reported health of people with heart disease. People with heart disease in the US report themselves to be in substantially better health than people in other countries, and the average in each of these other countries is roughly similar. 19 Of course, this does not prove that increased use of these procedures is the cause of improved health. To be more definitive about this, we would need to link data on self-reported health with the particular diagnosis and treatment that an individual received; neither of these are available in any of the data sets we examine. But the evidence is certainly consistent with the theory. Additional work using other data sets could usefully test these other predictions.
Diabetes. Diabetes mellitus is a chronic condition that impairs the body's ability to produce or store glucose. Type 1 diabetes is usually diagnosed in children and is a situation where the pancreas produces little or no insulin. Type 2 diabetes is far more common (accounting for 90 percent of diabetes cases) and occurs when the body does not effectively use the insulin it produces. Untreated or poorly treated, diabetes can cause severe problems, including vascular diseases (heart disease or stroke can result), small blood vessel disease (it can lead to blindness or 17 Ideally, utilization would be scaled by the share of people with an acute heart disease incident, but such data are not available. 18 In the terminology of the TECH group, the US is an "early start/fast growth" country, Canada belonged to the "late start/fast growth" group, and the UK to the "late start /slow growth" class. A similar conclusion was reached by the OECD Study of Cross National Differences in the Treatment, Cost and Outcomes of Ischaemic Heart Disease (2003), which concluded that a lot of the differences observed across countries are due to the different health care systems. They found that Canada and the UK provide very limited incentives to adopt cost-increasing new technologies due to their global budgets and strong programs to regulate technology adoption. 19 Related evidence suggesting that greater use of intensive care improves the health of Americans relative to Canadians is in Pilote at al. (1994) . That study made direct comparisons of functional status but did not normalize for the non-impaired group.
kidney disease) and nerve damage or neuropathy (it can lead to amputation). Some of these complications are controlled for in our analysis (heart disease, stroke , and visual problems ), and thus complications along these lines would not be associated with diabetes by itself. But not all complications would be picked up independently (kidney disease and nerve d amage, for example). Better treatment of diabetes could well improve health through these pathways.
Diabetes requires continuous monitoring and therapeutic intervention. Type 1 diabetes requires the intake of insulin regularly. Type 2 diabetes is controlled through exercise and meal planning and possibly medications and/or insulin. This monitoring requires a lot of selfcommitment, including self-testing of blood (about four times a day) and continuous diet and exercise control. This ongoing monitoring and treatment is provided in a chronic care setting, in contrast to the acute care treatments that are a larger factor for people with heart disease.
The success of the UK, Canada and, even more, Spain in the treatment of diabetes may come from differences in how they organize chronic care for diabetes. In particular, these countries stress a team-based approach that allows for an early detection of possible diabetes complications; they also emphasize training patients in methods of self -care. Further, substantial evidence shows that o utcomes can be improved with appropriate chronic care interventions, of the type that occur elsewhere. Introducing systems that stress physician monitoring, outreach, and appropriate interventions has been shown to result in large improvements in diabetes outcomes (Beaulieu, Cutler, and Ho, 2002) .
Thus, it is plausible that the poor organization of chronic disease care in the United States relative to other countries explains the difference in health outcomes for people with diabetes.
Again, this is not proof of this proposition. But it suggests a type of data analysis that can shed more light on this hypothesis. Unfortunately, the data we examine do not have information on the nature of diabetes care provided. Thus, this test will have to await the analysis of other data.
V. Conclusions
The US spends much more on health care than Canada, Spain or the UK. The natural question is whether that increased spending buys improved outcomes. It has long been clear that mortality as a whole is no better in the US than in other countries. What was less clear is whether there are differences in non-fatal health outcomes. Our results provide among the first comparative looks at this question.
We present a mixed message: the US does much better for people with some conditions (most particularly heart disease), but does worse on others (especially diabetes).
The discrepancy between high quality of life for some conditions and low quality of life for others is not attributable to differing performance by income: the poor and non-poor fare similarly in the US. Nor does it appear to be attributable to measurement issues in determining a
person's quality of life. We suggest that the difference may have to do with the nature of acute versus chronic disease care. The US tends to do better for conditions where there is an acute component to treatment: the availability and use of acute care is significantly greater in the US.
The US does poorly, in contrast, for conditions requiring substantial chronic disease management.
Countries that focus on this type of treatment seem to do much better. We suggest this hypothesis, and provide guidance on tests that might confirm or disprove it.
If this hypothesis is true, it raises the question about how medical systems are organized to treat various types of conditions. It may be that other countries focus on chronic disease care because they are cognizant of the limits on acute care and this is a reasonable substitute .
Alternatively, it may be easier to focus on non-high tech treatments outside of the private market, where financial incentives are much less important. The political economy of medical system development, along with the exact nature for the results we observe, will have to await further research. WHO (1996) , "Health Care Systems in Transition: Canada", World Health Organization, Regional Office for Europe. WHO (1996) , "Health Care Systems in Transition: Spain ", World Health Organization, Regional Office for Europe. WHO (1997) , "Highlights on Health in Spain", WHO Regional Office for Europe. **** * *** ** Skin/Allergy **** *** * *** Diabetes * *** **** ** Stomach * *** ** **** Heart/ Hypertension **** * *** ** Arthritis **** *** * ** Sight * **** *** ** Hearing **** * ** *** Hypertension *** ** **** Heart Problems **** ** *** Stroke **** *** Migraine *** **** Back Problems **** *** Cataracts *** **** Glaucoma *** 
